Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
ERA-63
Другие языки:

    ERA-63

    Подписчиков: 0, рейтинг: 0
    ERA-63
    ERA-63.svg
    Clinical data
    Other names 3-Methylene-7α-methylethinylestradiol; 3-Methylene-7α-methyl-17α-ethynylestra-5(10)-en-17β-ol
    Identifiers
    • (7R,8R,9S,13S,14S,17R)-17-Ethynyl-7,13-dimethyl-3-methylidene-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
    PubChem CID
    ChemSpider
    Chemical and physical data
    Formula C22H30O
    Molar mass 310.481 g·mol−1
    3D model (JSmol)
    • C[C@@H]1CC2=C(CCC(=C)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O
    • InChI=1S/C22H30O/c1-5-22(23)11-9-19-20-15(3)13-16-12-14(2)6-7-17(16)18(20)8-10-21(19,22)4/h1,15,18-20,23H,2,6-13H2,3-4H3/t15-,18-,19+,20-,21+,22+/m1/s1
    • Key:ITYURVXIFIQGDB-LADQHVHVSA-N

    ERA-63, also known as ORG-37663, as well as 3-methylene-7α-methyl-17α-ethynylestra-5(10)-en-17β-ol, is a synthetic, steroidal estrogen and a selective agonist of the ERα that was under development for the treatment of rheumatoid arthritis but was never marketed. The drug produced estrogenic effects but failed to show effectiveness for rheumatoid arthritis in a phase IIa clinical study. A large clinical trial also found that prinaberel (ERB-041), a selective ERβ agonist, was ineffective in the treatment of rheumatoid arthritis in spite of activity in preclinical models.

    See also



    Новое сообщение